CI — The Cigna Group
Is CI overbought or oversold? Here is the current MarketMoodz read.
The Cigna Group (CI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Healthcare Plans) last closed at $294.06. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$294.06
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryHealthcare Plans
See all oversold Healthcare stocks →
AI analysis
The Cigna Group (CI) combines a diversified insurer franchise and scale in PBM/health services that generate steady cash flow and shareholder return capacity. Near-term outlook is balanced: enrollment trends and Evernorth margin recovery are potential upside drivers while proposed CMS tightening of RADV and heightened political scrutiny introduce tangible regulatory and compliance risk. Earnings and regulatory developments over the coming weeks will likely drive directional movement; absent clear policy outcomes, expect consolidation around current levels with modest sensitivity to sector flows and company execution.
Key factors
- Diversified business mix: commercial, Medicare Advantage, Medicaid and Evernorth PBM/health services provide multiple revenue streams and stable cash flow.
- Strong financial position historically with consistent free cash flow, dividends and share buybacks supporting shareholder returns and balance-sheet flexibility.
- Medicare Advantage exposure: large membership base offers growth potential from aging demographics but creates sensitivity to CMS policy and RADV/regulatory changes.
- Operational scale and network advantages support pricing power and care-management capabilities relative to smaller competitors.
- Earnings cadence and sector flows: ongoing earnings reports and defensive interest in large-cap healthcare provide support for near-term stability.
- Potential upside catalysts include favorable enrollment trends, margin improvement in Evernorth, successful cost containment and any positive regulatory clarifications.
Risks
- Regulatory risk to Medicare Advantage economics from CMS proposals increasing RADV scrutiny and anti-fraud measures, which could trigger clawbacks or higher compliance costs.
- Political and reputational risk from high-profile criticism (e.g., Elizabeth Warren) and potential legislative or antitrust scrutiny of integrated insurer/PBM models.
- PBM and specialty pharmacy reimbursement pressure or competitive disruption could compress Evernorth margins and reduce fee-based revenue.
- Execution risk on care-management and cost initiatives; failure to control medical cost trend could hurt margins.
- Macroeconomic pressure on employer-sponsored enrollment or adverse changes in payer/provider reimbursement dynamics.
- Legal, cybersecurity, or large claims events that could produce outsized costs or operational disruption.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for CI — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.